Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827872) titled 'Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: caohaotian
Condition:
Oral Squamous Cell Carcinoma (OSCC)
Head and Neck Squamous Cell Carcinoma
Early-stage Oral Cancer
Intervention:
Drug: Sintilimab
Drug: Nab-Paclitaxel
Drug: Carboplatin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 1, 2026
Target Sample Size: 300
Countries of Recruitment:
C...